Zacks Investment Research
08 Jun 2026, 16:55 UTC · 2h ago
Is Altimmune Worth Buying Ahead of 2026 Catalysts?
Zacks Investment Research
08 Jun 2026, 16:55 UTC · 2h ago
Story key points
4 claims · impact-rated
Altimmune plans to start a global phase III registrational study for pemvidutide in metabolic dysfunction-associated steatohepatitis in the second half of 2026. — Moving into a pivotal phase III study is a critical gating event for drug approval and company valuation.
+0.60Top-line phase II data from the RECLAIM study in alcohol use disorder is expected in the third quarter of 2026. — Phase II results provide the first major proof-of-concept for this indication, potentially expanding the asset's market.
+0.40Altimmune's valuation is heavily concentrated on pemvidutide, creating a high-risk binary profile where failure in pivotal programs would cause significant downside. — High asset concentration increases volatility and risk of a major price collapse if a lead drug fails.
-0.30Continue reading
6 related stories
Top 2 movers · tap to explore
Enrollment for the RESTORE phase II study in alcohol-associated liver disease is expected to be completed by the third quarter of 2026. — Enrollment completion is a positive sign of operational execution, though it does not confirm efficacy.
+0.20Ticker attribution
Model heads
The company has several upcoming clinical catalysts and a lead asset with a clear path toward a phase III study.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
2 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Seeking Alpha
9h ago
